Linkage Biosciences

Linkage Biosciences

Manufacturer of genotyping kits for use in human hla and kir typing, as well as blood genotyping for rbc, rh, abo, and hpa. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€7—11m (Dealroom.co estimates May 2013.)
San Francisco California (HQ)
  • Edit
DateInvestorsAmountRound
N/A

$1.0m

Seed

$2.0m

Series A
N/A

$2.0m

Early VC

$2.1m

Series B

$2.0m

Early VC

$1.5m

Early VC

$2.0m

Early VC

N/A

Acquisition
Total Funding€11.5m

Recent News about Linkage Biosciences

Edit
More about Linkage Biosciencesinfo icon
Edit

Linkage Biosciences specializes in advanced diagnostic tests that determine donor compatibility before transplants and monitor HLA antibodies post-transplant to prevent rejection. Operating in the healthcare and biotechnology market, the company serves hospitals, transplant centers, and laboratories. Its business model revolves around the development and sale of diagnostic assays, leveraging multiplex PCR technology for simplicity and efficiency. Revenue is generated through the sale of these diagnostic kits and related services. Linkage Biosciences aims to support the transplantation community with innovative solutions and resources, particularly during challenging times like the Covid-19 pandemic.

Keywords: diagnostic tests, donor compatibility, HLA antibodies, transplant success, multiplex PCR, healthcare, biotechnology, transplant centers, diagnostic assays, Covid-19.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Linkage Biosciences

Edit
Microbia
ACQUISITION by DSM (Formerly Koninklijke DSM N.V., Koninklijke DSM, DSM N.V.) Sep 2010